You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Moodys
McKinsey
McKesson

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Bardoxolone methyl

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Bardoxolone methyl?

Bardoxolone methyl is an investigational drug.

There have been 29 clinical trials for Bardoxolone methyl. The most recent clinical trial was a Phase 2 trial, which was initiated on April 18th 2017.

The most common disease conditions in clinical trials are Kidney Diseases, Renal Insufficiency, Chronic, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., and NYU Langone Health.

There are forty-four US patents protecting this investigational drug and two hundred and fifty-eight international patents.

Recent Clinical Trials for Bardoxolone methyl
TitleSponsorPhase
A Phase 2 Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)Reata Pharmaceuticals, Inc.Phase 2
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)Reata Pharmaceuticals, Inc.Phase 2/Phase 3
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)NYU Langone HealthPhase 2/Phase 3

See all Bardoxolone methyl clinical trials

Clinical Trial Summary for Bardoxolone methyl

Top disease conditions for Bardoxolone methyl
Top clinical trial sponsors for Bardoxolone methyl

See all Bardoxolone methyl clinical trials

US Patents for Bardoxolone methyl

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bardoxolone methyl   Start Trial Methods for the prevention and the treatment of rapidly progressive glomerulonephritis INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DESCARTES (Paris, FR)   Start Trial
Bardoxolone methyl   Start Trial Oxidative retinal diseases Retrotope, Inc. (Los Altos, CA)   Start Trial
Bardoxolone methyl   Start Trial Impaired energy processing disorders and mitochondrial deficiency Retrotope, Inc. (Los Altos, CA)   Start Trial
Bardoxolone methyl   Start Trial Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17 REATA PHARMACEUTICALS, INC. (Irving, TX)   Start Trial
Bardoxolone methyl   Start Trial Disorders implicating PUFA oxidation Retrotope, Inc. (Los Altos, CA)   Start Trial
Bardoxolone methyl   Start Trial Neurodegenerative disorders and muscle diseases implicating PUFAs Retrotope, Inc. (Los Altos, CA)   Start Trial
Bardoxolone methyl   Start Trial Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof vTv Therapeutics LLC (High Point, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bardoxolone methyl

Drugname Country Document Number Estimated Expiration Related US Patent
Bardoxolone methyl World Intellectual Property Organization (WIPO) WO2016071727 2034-11-04   Start Trial
Bardoxolone methyl Australia AU2012249921 2031-04-26   Start Trial
Bardoxolone methyl Canada CA2834341 2031-04-26   Start Trial
Bardoxolone methyl Denmark DK2701697 2031-04-26   Start Trial
Bardoxolone methyl European Patent Office EP2701697 2031-04-26   Start Trial
Bardoxolone methyl European Patent Office EP3689342 2031-04-26   Start Trial
Bardoxolone methyl Israel IL229017 2031-04-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.